QTTB (Q32 Bio) Piotroski F-Score: 5 (As of Jul. 07, 2026) — 25% Above Median


QTTB Q32 Bio Inc QTTB
17 GF Score
Price $12.84
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Piotroski F-Score?

Q32 Bio QTTB -1.72% 17 Piotroski F-Score is 5 as of Jul. 07, 2026, which is 25% above its 10-year median of 4.00. GuruFocus rates QTTB with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 1,332 Biotechnology companies, Q32 Bio ranks better than 84.98% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Q32 Bio has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Q32 Bio's Piotroski F-Score or its related term are showing as below:

QTTB' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 5 years, the highest Piotroski F-Score of Q32 Bio was 5. The lowest was 2. And the median was 4.

Q32 Bio  (NAS:QTTB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Q32 Bio Piotroski F-Score Related Terms


Q32 Bio Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Piotroski F-Score Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A N/A 3.00 4.00

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 4.00 4.00 5.00

QTTB vs CAMP, CDXS, KROS: Piotroski F-Score Comparison

For the Biotechnology subindustry, Q32 Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Piotroski F-Score falls into.


QTTB
17GF Score
Q32 Bio Inc QTTB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -9.489 + -7.389 + 57.73 + -7.609 = $33.24 Mil.
Cash Flow from Operations was -10.651 + -4.23 + -6.18 + -6.343 = $-27.40 Mil.
Revenue was 0 + 0 + 53.737 + 0 = $53.74 Mil.
Gross Profit was 0 + 0 + 53.737 + 0 = $53.74 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(79.071 + 66.117 + 57.784 + 61.776 + 63.675) / 5 = $65.6846 Mil.
Total Assets at the begining of this year (Mar25) was $79.07 Mil.
Long-Term Debt & Capital Lease Obligation was $6.69 Mil.
Total Current Assets was $57.20 Mil.
Total Current Liabilities was $10.67 Mil.
Net Income was -16.978 + -17.595 + -14.189 + -11.031 = $-59.79 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(152.334 + 124.207 + 104.542 + 92.332 + 79.071) / 5 = $110.4972 Mil.
Total Assets at the begining of last year (Mar24) was $152.33 Mil.
Long-Term Debt & Capital Lease Obligation was $13.51 Mil.
Total Current Assets was $68.63 Mil.
Total Current Liabilities was $14.58 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Q32 Bio's current Net Income (TTM) was 33.24. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Q32 Bio's current Cash Flow from Operations (TTM) was -27.40. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=33.243/79.071
=0.42041962

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-59.793/152.334
=-0.39251251

Q32 Bio's return on assets of this year was 0.42041962. Q32 Bio's return on assets of last year was -0.39251251. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Q32 Bio's current Net Income (TTM) was 33.24. Q32 Bio's current Cash Flow from Operations (TTM) was -27.40. ==> -27.40 <= 33.24 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=6.693/65.6846
=0.10189603

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=13.506/110.4972
=0.12222934

Q32 Bio's gearing of this year was 0.10189603. Q32 Bio's gearing of last year was 0.12222934. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=57.202/10.669
=5.36151467

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=68.632/14.579
=4.70759311

Q32 Bio's current ratio of this year was 5.36151467. Q32 Bio's current ratio of last year was 4.70759311. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Q32 Bio's number of shares in issue this year was 14.095. Q32 Bio's number of shares in issue last year was 12.198. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=53.737/53.737
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Q32 Bio's gross margin of this year was 1. Q32 Bio's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=53.737/79.071
=0.67960441

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=0/152.334
=0

Q32 Bio's asset turnover of this year was 0.67960441. Q32 Bio's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+1+0+1+1+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Q32 Bio has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Q32 Bio (QTTB) has a Piotroski F-Score of 5 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Q32 Bio and its competitors. This is 25% above median its historical median of 4.00. Over the past decade, Q32 Bio's Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Q32 Bio ranks #200 out of 1332 companies in the Biotechnology industry, placing it in the top 15%.
Is Q32 Bio's Piotroski F-Score too high?
Q32 Bio's current Piotroski F-Score of 5 is 25% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Biotechnology industry median Piotroski F-Score is 3.00. Q32 Bio's value of 5 is 66.7% above this industry median. Based on the distribution chart, Q32 Bio ranks #200 out of 1332 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Piotroski F-Score compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #200 out of 1332 companies for Piotroski F-Score. This places Q32 Bio in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Q32 Bio's value of 5 is 66.7% above this benchmark. Historically, Q32 Bio's own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Q32 Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,332 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q32 Bio's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Q32 Bio and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current Piotroski F-Score is 5, which is 25% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (QTTB) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is 25% above median its 10-year median of 4.00 and 66.7% above the Biotechnology industry median of 3.00. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Q32 Bio (QTTB), the current Piotroski F-Score is 5 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges DB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for QTTB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.84
Price